VX-710 inhibitor of the MDR-1 P-glycoprotein pump that removes cancer drugs from cells: Began Phase I trial to assess VX-710 in combination with doxorubicin, in

Vertex Pharmaceuticals Inc. (VRTX), Cambridge, Mass. Product: VX-710 inhibitor of the MDR-1 P-glycoprotein pump that removes cancer drugs from cells; it also blocks a newly discovered pump, MRP Indica...